Tildrakizumab manufacturers
- Tildrakizumab
-
- $745.00
-
2026-07-27
- CAS:1326244-10-3
- Purity: > 95%
- Supply Ability: 10g
|
| | Tildrakizumab Basic information |
| Product Name: | Tildrakizumab | | Synonyms: | Tildrakizumab;Research Grade Tildrakizumab(DHJ63102);MK 3222|||SCH 900222;Research Grade Tildrakizumab;Tildrakizumab (anti-IL-23a) | | CAS: | 1326244-10-3 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Tildrakizumab Structure]() |
| | Tildrakizumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Tildrakizumab Usage And Synthesis |
| Uses | Tildrakizumab (SCH 900222) is a humanized anti-IL-23 (p19 subunit) monoclonal antibody. IL-23 is a critical cytokine to maintain the Th17 cell phenotype. Tildrakizumab has high-affinity for single-chain IL-23 (Kd: 136 pM). Tildrakizumab is effective against moderate to severe plaque psoriasis[1][2][3]. | | in vivo | Tildrakizumab (100mg/kg, s.c., every 2 weeks up to 9 months) is well tolerated in cynomolgus monkeys (toxicity studies)[3].
| | References | [1] Papp K, et al. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015 Oct;173(4):930-9. DOI:10.1111/bjd.13932
[2] Zhou L, et al. A non-clinical comparative study of IL-23 antibodies in psoriasis. MAbs. 2021 Jan-Dec;13(1):1964420. DOI:10.1080/19420862.2021.1964420
[3] Santostefano M, et al. Nonclinical safety of tildrakizumab, a humanized anti-IL-23p19 monoclonal antibody, in nonhuman primates. Regul Toxicol Pharmacol. 2019 Nov;108:104476. DOI:10.1016/j.yrtph.2019.104476 |
| | Tildrakizumab Preparation Products And Raw materials |
|